Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: An Analysis of 35 Consecutive Patients

Salvatore Palumbo1, Kimon Bekelis2, Symeone Missios3

  • 1Neurosurgery, Good Samaritan University Hospital, West Islip, USA.

Cureus
|December 21, 2023
PubMed
Abstract

Insights

Middle meningeal artery embolization (MMAE) is effective for chronic subdural hematomas (cSDH), with or without adjuvant surgical drainage (ASD). Only 9% of patients required further intervention, and no ASD patients experienced recurrence.

Area of Science:

  • Neurosurgery
  • Interventional Radiology
  • Vascular Surgery

Background:

  • Chronic subdural hematomas (cSDH) can be treated with minimally invasive middle meningeal artery embolization (MMAE).
  • Favorable outcomes are documented in scientific literature for MMAE in cSDH treatment.
  • This study evaluates MMAE outcomes, with and without adjuvant surgical drainage (ASD), to identify outcome-influencing variables.

Purpose of the Study:

  • To evaluate the outcomes of patients treated with MMAE for cSDH.
  • To compare MMAE with and without ASD.
  • To identify variables affecting MMAE outcomes in cSDH patients.

Main Methods:

  • Multivariate retrospective analysis of 35 consecutive cSDH patients treated with MMAE.
  • Variables analyzed included age, cSDH size, ASD use, collection laterality, and anticoagulant use.
  • Comparison of outcomes between MMAE-only and MMAE with ASD groups.

Main Results:

  • MMAE with ASD (n=20) and MMAE only (n=15) showed average cSDH size reductions of 74% and 69%, respectively.
  • Only 3 of 35 patients (9%) required rescue craniotomy; none of the 20 patients receiving ASD had recurrence.
  • Anticoagulant use was associated with slightly lower size reduction (71-74%) compared to non-anticoagulant users (78-84%).

Conclusions:

  • MMAE, with or without ASD, is a viable alternative or adjunct to standard surgical treatment for cSDH.
  • The low rate of subsequent surgical intervention (9%) highlights MMAE's efficacy.
  • Further prospective studies are needed to optimize patient selection and understand outcome variables for MMAE in cSDH.